Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Verified Market Research | PRODUCT CODE: 1736743

Cover Image

PUBLISHER: Verified Market Research | PRODUCT CODE: 1736743

Global Optic Nerve Disorders Treatment Market Size By Type of Treatment (Eye Drops, Steroids), By Type of Nerve Disorder (Glaucoma, Optic neuritis), By End User (Hospitals, Ophthalmology Clinics), By Geographic Scope And Forecast

PUBLISHED:
PAGES: 202 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3950
PDF & Excel (5 User License)
USD 4850
PDF & Excel (Enterprise User License)
USD 7550

Add to Cart

Optic Nerve Disorders Treatment Market Size And Forecast

Optic Nerve Disorders Treatment Market size was valued at USD 3.6 Billion in 2024 and is projected to reach USD 5.7 Billion by 2032, growing at a CAGR of 4.7% during the forecast period 2026-2032.

Optic neuritis is a condition in which the optic nerve, a group of nerve fibers that transmits visual information from the eye to the brain, is destroyed by inflammation (swelling). Optic neuritis is characterized by temporary vision loss in one eye and discomfort with eye movement. Due to the rising prevalence of optic illnesses, the adoption of a sedentary lifestyle, and the rising incidence of lifestyle diseases like diabetes, Blood Pressure & Hypertension, the global market for treatments for optic nerve disorders is anticipated to grow over the course of the forecasted period. The market is comprehensively evaluated in the study on the global market for treating optic nerve disorders.

Global Optic Nerve Disorders Treatment Market Definition

The cranial nerves that connect the retinal cells to the optic chiasm are known as the optic nerves. The retina's photoreceptor cells take in light and send electric impulses to the brain through the optic nerves. Loss of vision could result from malfunction or damage to the optic nerves, depending on the type and location of the lesion. One or both eyes could experience vision impairment. Electrical signals are sent from retinal photoreceptor cells via the optic nerve to the brain's visual cortex.

Any damage to the optic nerve or its pathways has the potential to permanently harm the eyes and cause vision loss. One of the most frequent conditions that might harm the optic nerve is optic neuritis. The optic nerve is inflamed as a result of damage to or loss of myelin, the protective covering that covers it. Optic neuritis may be brought on by inflammation and myelin breakdown, according to researchers. The two nerves perform an essential task and converge at the optic chiasm.

Half of each side's nerve fibers cross over to the other side as the optic nerve splits in half. Injury and the removal of the nerve's protective covering both cause inflammation of the nerve. Glaucoma, optic neuritis, atrophy of the optic nerve, and optic disc drusen (ODD), among other conditions, are optic nerve disorders. Therapy options include corticosteroids, intravenous immune globulin (IVIG)/plasma exchange, vitamin B12 injection, and surgery, among others, depending on the degree and kind of disease identified.

Global Optic Nerve Disorders Treatment Market Overview

In 2019, 2.2 billion individuals worldwide experienced visual impairment or blindness, according to WHO. Out of these, cataracts, uncorrected refractive errors, glaucoma, corneal opacification, etc. are the main causes of vision impairment. One significant factor that contributes to the increase in fluid pressure in the eye, which worsens optic nerve damage, is glaucoma. It is frequently inherited by people, although it can also be brought on by an infection, an eye injury from chemicals, etc. Early detection and treatment options include eye drops, oral drugs, and operations like laser therapy.

Multiple sclerosis (MS), an autoimmune condition associated with the immune system attacking the body's healthy cells, is the primary cause of optic neuritis. Due to lowered immunity, MS is becoming more common in the aging population, while it can also be brought on by diabetes, smoking, infections, etc. Due to sedentary lifestyles, bad diets, lack of physical activity, etc., there is an increase in lifestyle disorders like diabetes, blood pressure, hypertension, etc., which further increases the likelihood that MS may cause ocular neuritis. The percentage of persons who need therapy for the disease is increasing as a result. Steroids are typically used to treat optic neuritis in order to prevent the condition's future progression.

Although there is no definitive cure for optic nerve illnesses, there is a lot of emphasis on preventing them and finding them early to avoid complications from medication, medications, and surgery. The increase in the elderly population and the growing awareness of the need for early diagnosis to stop the condition from getting worse has increased the demand for drugs and surgeries for treating optic nerve disorders, which has fueled the growth of the market for those treatments. However, the market's expansion is being hampered by potential side effects associated with the usage of medications for the treatment of optic nerve disorders like glaucoma, such as changing eye color, sunken eyes, itching, etc.

Global Optic Nerve Disorders Treatment Market Segmentation Analysis

The Global Optic Nerve Disorders Treatment Market is segmented on the basis of Type of Treatment, Type of Nerve Disorder, End User, And Geography.

Optic Nerve Disorders Treatment Market, By Type of Treatment

  • Eye Drops
  • Steroids
  • Intravenous immune Globulin/ Plasma Exchange
  • Vitamin B12 injection
  • Surgery

Based on Type of Treatment, The market is segmented into Eye Drops, Steroids, Intravenous immune globulin (IVIG)/Plasma Exchange, Vitamin B12 injection, and Surgery. Due to their simplicity of use, quick start of the action, and increased efficacy, eye drops are predicted to experience the largest growth during the estimated period.

  • Numerous common disorders are treated using eye drops. They can be used for tired, itchy eyes brought on by allergies. They might be recommended for bacterial or viral infections as well as other disorders like glaucoma. The entire therapeutic benefit of the drug might not be experienced when eye drops are not properly administered or used.

Optic Nerve Disorders Treatment Market, By Type of Nerve Disorder

  • Glaucoma
  • Optic neuritis
  • Others

Based on Type of Nerve Disorder, The market is segmented into Glaucoma, Optic neuritis, and Others. Due to a lack of knowledge about glaucoma and the rising elderly population, glaucoma is anticipated to rise the most during the anticipated time. due to an increase in open-angle glaucoma prevalence. Additionally, it is projected that an increase in the number of medications approved for the treatment of open-angle glaucoma will spur market expansion.

  • Additionally, the market for treatments for optic neuritis is anticipated to increase at the quickest rate throughout the anticipated period. This is ascribed to the rise in optic neuritis prevalence, the availability of reimbursement policies, and rising public awareness of multiple sclerosis driving the market expansion.

Optic Nerve Disorders Treatment Market, By End User

  • Hospitals
  • Ophthalmology Clinics
  • Ambulatory Surgical Centers

Based on End User, The market is segmented into Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers. Due to the increased prevalence of optical disorders, accessibility to cutting-edge technology, and well-established healthcare infrastructure, the hospital segment is anticipated to grow the most throughout the anticipated period.

  • The availability of enhanced healthcare infrastructure, the rise in unmet healthcare needs, the rise in the prevalence of eye disease, and the spike in demand for medications to treat optic nerve disorders all point to high promise in unexplored, emerging markets. Additionally, the desire for better healthcare services, large government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the healthcare sector in emerging economies.

Optic Nerve Disorders Treatment Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Based on Geography, The Global Optic Nerve Disorders Treatment Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Due to its high illness prevalence, accessibility of reimbursement policies, and rising public awareness of multiple sclerosis and optic neuritis, the Asia Pacific area is anticipated to rise more than any other region throughout the forecasted period.

  • The market has grown in this area due to the presence of pharmaceutical companies there as well as the increasing purchasing power of populous countries like China and India. The market is expanding due to the aging population as well as the rising prevalence of diseases affecting the optic nerve, including glaucoma and optic neuritis.

Key Players

The "Global Optic Nerve Disorders Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bionure Farma S.L., Teva Pharmaceutical Industries Ltd, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Allergan plc., Aerie Pharmaceuticals Inc, Mallinckrodt Pharmaceuticals, Merck Sharp & Dohme Corp, and Bausch Health Companies, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

  • In February 2022, The results of a recent trial conducted by Horizon Therapeutics plc (Nasdaq: HZNP) showed that UPLIZNA medication effectively reduced the intensity of attacks in NMOSD patients.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Optic Nerve Disorders Treatment Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in Global Optic Nerve Disorders Treatment Market gauge the attractiveness of a certain sector, and assess investment possibilities.
Product Code: 40550

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data mining
  • 2.2 Secondary research
  • 2.3 Primary research
  • 2.4 Subject matter expert advice
  • 2.5 Quality check
  • 2.6 Final review
  • 2.7 Data triangulation
  • 2.8 Bottom-up approach
  • 2.9 Top-down approach
  • 2.10 Research flow
  • 2.11 Data sources

3 EXECUTIVE SUMMARY

  • 3.1 Overview
  • 3.2 Absolute $ Opportunity
  • 3.3 Market attractiveness
  • 3.4 Future Market Opportunities

4 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF TREATMENT

  • 5.1 Overview
  • 5.2 Eye Drops
  • 5.3 Steroids
  • 5.4 Intravenous immune Globulin/ Plasma Exchange
  • 5.5 Vitamin B12 injection
  • 5.6 Surgery

6 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF NREVE DISORDER

  • 6.1 Overview
  • 6.2 Glaucoma
  • 6.3 Optic neuritis
  • 6.4 Others

7 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Ophthalmology Clinics
  • 7.4 Ambulatory Surgical Centers

8 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 Bionure Farma S.L.
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Teva Pharmaceutical Industries
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Santen Pharmaceutical
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Novartis AG
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Pfizer
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Allergan
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 Aerie Pharmaceuticals
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 Mallinckrodt Pharmaceuticals
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 Merck Sharp & Dohme Corp
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 Bausch Health Companies
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 APPENDIX

  • 12.1 Related Research
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!